De Backer Marianne 4

What Happened Marianne De Backer, CEO of Vir Biotechnology (VIR), sold 14,762 shares on 2026-02-24 at $9.53 per share, generating proceeds of $140,720. The filing shows this was a sale (S) and, per the filer, an automatic transaction to satisfy tax withholding tied to vesting restricted stock units—not a discretionary trade.

Key Details

• Transaction date: 2026-02-24; Filing date: 2026-02-26 (timely).
• Price: $9.53 per share; Shares sold: 14,762; Gross proceeds: $140,720.
• Reason/footnote: Sale executed under a Rule 10b5-1 arrangement to cover tax withholding on RSU vesting (automatic/mandatory; not discretionary).
• Shares held in the name of the Ureel‑De Backer Family Trust; Marianne De Backer and her spouse are trustees (per footnote).
• Shares owned after the transaction: not specified in the filing.

Context This was a sale to satisfy tax obligations related to vested restricted stock units, a common and typically routine insider transaction; it should not be interpreted as a discretionary signal about company prospects. For retail investors, purchases by insiders tend to be more indicative of bullish sentiment than tax‑withholding sales like this one.